GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (OTCPK:WXXWY) » Definitions » Buyback Yield %

WuXi Biologics (Cayman) (WuXi Biologics (Cayman)) Buyback Yield % : 4.27 (As of Apr. 27, 2024)


View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

WuXi Biologics (Cayman)'s current buyback yield was 4.27%.


WuXi Biologics (Cayman) Buyback Yield % Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Buyback Yield % Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.13 -1.61 -2.68 1.25 -

WuXi Biologics (Cayman) Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 0.52 1.89 -0.02 -

Competitive Comparison of WuXi Biologics (Cayman)'s Buyback Yield %

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WuXi Biologics (Cayman)'s Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Buyback Yield % distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s Buyback Yield % falls into.



WuXi Biologics (Cayman) Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

WuXi Biologics (Cayman)'s Buyback Yield for the fiscal year that ended in Dec. 2022 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-402.263 + 5.19) / 31837.3341
=1.25%

WuXi Biologics (Cayman)'s annualized Buyback Yield for the quarter that ended in Jun. 2023 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 1.816) * 2 / 20435.3812
=-0.02%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized semi-annual data, the Repurchase of Stock and Issuance of Stock data used here is two times the semi-annual (Jun. 2023) data.


WuXi Biologics (Cayman) Buyback Yield % Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi Biologics (Cayman) (WuXi Biologics (Cayman)) Business Description

Address
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.